Minimed Group, Inc. announced a director or officer change; made a public disclosure
SEC 8-KRead source ↗
Minimed Group, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$13
Valuation models combined (2)
Base case. Range ~$11–$16. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers).
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Minimed Group, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds73 adding, 26 cuttingOf 30 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 38% in the quarter to 2026-07-31.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Estimates rising. Analysts' consensus for next year's earnings per share has risen 5.1% over 90 days.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 57% and a beta of 0.8 against the S&P 500.
- Heavily shorted. 72.6% of the shares available to trade are sold short (1.6 days of average volume to cover).
- Earnings expected to fall. The consensus expects earnings per share to fall 1% next year.
Latest results
- Earnings per share
- $0.13 against an average estimate of $0.10: beat by 37.8%
- Share reaction
- +17.3% in the first session after the results on September 1, 2026, against -0.2% for the S&P 500
- Next report
- November 16, 2026; average EPS estimate $0.10
Price chart
- 1 day+3.4%
- 1 week+1.3%
- 1 month-4.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- September 1, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Leadership
- Shareholder vote
Minimed Group, Inc. reported shareholder vote results
SEC 8-KRead source ↗ - Results
Minimed Group, Inc. reported results; made a public disclosure
SEC 8-KRead source ↗ - Leadership
Minimed Group, Inc. announced a director or officer change
SEC 8-KRead source ↗
Valuation models
We value Minimed Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$11 ~$10–$18 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$16 ~$17–$61 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$13 ~$11–$16 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Minimed Group, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Next results: November 16, 2026, before the open. Analysts expect revenue of $824m and EPS of $0.10 (range $0.06 to $0.14) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.70 | +226% | $3.4bn | +16% |
| Next | $0.69 | −1% | $3.7bn | +9% |
Next year's EPS estimate has moved +5.1% in 90 days, across 11 analysts.
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +11.3% on 90 days ago. In the last 30 days, 1 analyst raised Minimed Group, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $0.63 | $0.66 |
| 60 days ago | $0.62 | $0.66 |
| 30 days ago | $0.67 | $0.64 |
| 7 days ago | $0.70 | $0.69 |
| Now | $0.70 | $0.69 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $0.10 | $0.13 | +37.8% |
| Apr 2026 | −$0.22 | −$0.60 | −171.8% |
| Jan 2026 | $0.21 | $0.08 | −63.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 72.6% of tradable shares
- Days to cover
- 1.61 at average volume
- Short interest, 1 month
- +52% to October 15, 2026
- Held by institutions
- 21% of shares
- Held by insiders
- 0.1% of shares
- Employees
- 8,000 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −6.1%
- vs 200-day average
- —
- Volatility (1 year)
- 57%
- Beta vs S&P 500
- 0.83
Share price after results
- Next day
- 2 up, 0 down typical move ±15.8%
- After a week
- 2 up, 0 down typical move ±16.0%
- After a month
- 1 up, 1 down typical move ±13.8%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| September 1, 2026 | +17.3% | −0.2% | +12.3% | −3.3% |
| June 3, 2026 | +14.3% | −0.3% | +19.6% | +24.3% |
Fundamentals
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Continuous Glucose Monitoring Systems CGM | $1.6B | 50.1% | ▲ 18.3% |
| Consumables | $956M | 30.8% | ▲ 11.9% |
| Pumps | $546M | 17.6% | ▲ 0.9% |
| Other | $46M | 1.5% | ▲ 666.7% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| Outside the US | $2.2B | 70.4% | ▲ 20.6% |
| United States | $917M | 29.6% | ▲ 1.6% |
From Minimed Group, Inc.'s 10-K filed June 29, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $557M
- Institutions reporting
- 97
- Shares held vs prior quarter
- ▲ 14.7%
- Positions opened / closed
- 52 / 13
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Massachusetts Financial Services Co | $125M | 8.3M | 22.4% | ▲ 21.2% |
| Millennium Management LLC | $45.8M | 3.1M | 8.2% | ▲ 18.0% |
| Citadel Advisors LLC | $42.8M | 2.9M | 7.7% | ▲ 0.5% |
| Longaeva Partners L.P. | $42.1M | 2.8M | 7.6% | ▼ 11.5% |
| Sessa Capital Im, L.P. | $29.9M | 2.0M | 5.4% | 0.0% |
| Blackrock, Inc. | $29.8M | 2.0M | 5.4% | ▲ 7527.5% |
| Norges Bank | $29.3M | 2.0M | 5.3% | — |
| Rock Springs Capital Management LP | $22.7M | 1.5M | 4.1% | ▲ 44.1% |
| Exoduspoint Capital Management, LP | $21.5M | 1.4M | 3.9% | ▲ 251.1% |
| FMR LLC | $16.2M | 1.1M | 2.9% | ▼ 20.8% |
| Geode Capital Management, LLC | $14.3M | 956K | 2.6% | ▲ 288.7% |
| Boston Partners | $13.5M | 902K | 2.4% | ▲ 6.8% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Minimed Group, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- September 1, 2026
- June 3, 2026
Recent SEC filings
- 8-K Current report
- 8-K Current report
- S-4 S-4
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Minimed Group, Inc. in brief
- What does Minimed Group, Inc. do?
- Minimed Group, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
- What is Minimed Group, Inc.'s stock ticker?
- Minimed Group, Inc. trades under the ticker MMED on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Minimed Group, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Massachusetts Financial Services Co, Millennium Management LLC and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Minimed Group, Inc.'s next earnings date?
- Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Minimed Group, Inc. announces its own schedule.
Follow research on Minimed Group, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.